Author/Authors :
azizi, ebrahim zanjan university of medical sciences - faculty of medicine - department of genetics, zanjan, iran , azizi, ebrahim tehran university of medical sciences (tums) - cancer biology research center, cancer institute of iran, tehran, iran , biglari, alireza zanjan university of medical sciences - faculty of medicine - department of genetics, zanjan, iran , kian saei, ali tehran university of medical sciences (tums) - cancer biology research center, cancer institute of iran, tehran, iran , amanpour, saeid tehran university of medical sciences (tums) - cancer biology research center, cancer institute of iran, tehran, iran , muhammadnejad, samad tehran university of medical sciences (tums) - cancer biology research center, cancer institute of iran, tehran, iran , haddadi, mahnaz tehran university of medical sciences (tums) - cancer biology research center, cancer institute of iran, tehran, iran , saffari, mojtaba tehran university of medical sciences (tums) - faculty of medicine - department of genetics, tehran, iran , shirkoohi, reza tehran university of medical sciences (tums) - cancer biology research center, cancer institute of iran, tehran, iran
Abstract :
background: this study investigated the possible role of genistein as a combination with imatinib in controlling leukemia cell line proliferation. methods: three cell lines, k562, kcl22, and ccrf, were cultured and analyzed for mtt, ldh, apoptosis, and cycle cell gene expression in the presence of different dosages of imatinib and genistein in combination or separately. results: data has shown a decrease in proliferation and an increase in apoptosis activity during combination treatment. ldh assay has shown no additional toxicity due to genistein consumption in combination therapy. analysis of the expression of responsible genes for cell cycle demonstrated both g1 (p53, p21 upregulation) and g2 (cdc25c downregulation) inhibitory effect in combination treatment. conclusion: altogether, this study suggests thatthe combination treatment of imatinib and genistein for leukemia cells resistant to imatinib can increase treatment efficiency.
Keywords :
cell cycle , genistein , imatinib , leukemia , philadelphia chromosome